Integer Holdings has reached a definitive agreement to be bought by an affiliate of investment funds managed by KKR, in an all-cash transaction valuing the company at approximately $5.7bn.
Under the arrangement, all outstanding shares of Integer Holdings will be purchased for $127 per share in cash.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The offer represents a premium of 51.8% to Integer Holdings’ closing share price on 29 April 2026, which was the day before the company announced a strategic review, and a 28.8% premium to the 30-day volume-weighted average price as of 31 July 2026.
Integer Holdings’ Board of Directors has unanimously approved the transaction and is recommending that shareholders vote in favour of the agreement. The acquisition follows a comprehensive strategic review that began on 30 April 2026.
The board consulted with management and external advisers to consider several alternatives prior to selecting KKR’s offer as the preferred option.
Integer Holdings president and CEO Payman Khales said: “This is an exciting milestone for Integer and a testament to the dedication and commitment of our talented team and the exceptional business we have built together.
“We believe this transaction recognises the strength of Integer’s business, which includes our dedicated associates, our differentiated engineering and manufacturing capabilities, and our long-term growth opportunities, while providing stockholders with immediate and certain value.
“KKR’s deep healthcare expertise, long-term vision, and strategic growth orientation make them the right strategic partner to bring our business into its next chapter.”
Upon completion of the transaction, Integer Holdings is expected to become a privately held company and its shares will be removed from the New York Stock Exchange.
KKR has indicated plans to establish an employee ownership scheme at Integer, consistent with its approach across other portfolio companies.
Completion of the deal is subject to shareholder and regulatory approvals and is anticipated by the end of the year.